FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
BioSyntech, Inc. Stock AnalysisComprehensive stock analysis for BioSyntech, Inc. (BSYI) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBSYI
BSYI
BioSyntech, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
BSYI
Home🔹Stocks🔹BioSyntech, Inc.

BioSyntech, Inc.

BSYI•OTC

BioSyntech, Inc.

BSYI•OTC
Market cap
$229.03K
Sentiment

Your view on BSYI

Mkt Cap
$229.03K
Sentiment
Your view
BSYI
BioSyntech, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
BSYI
Company Overview

Overview

What the company does, where it operates, and who runs it.

About BioSyntech, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Amine Selmani
Headquarters
475 Armand-Frappier Boulevard, Laval, QC, CA
Industry
Biotechnology
Sector
Healthcare
CEO
Amine Selmani
Headquarters
475 Armand-Frappier Boulevard, Laval, QC, CA
Description

BioSyntech, Inc. develops biotherapeutic thermogels for tissue repair and therapeutic delivery. Its lead products in development include BST-CarGel, a biodegradable gel for cartilage repair; BST-InPod for heel pain relief; BST-DermOn for chronic wound healing; BST-Ossifil for bone filling; BST-Ossifix for bone structural support; and BST-Disc for intervertebral disc restoration. The company's products also comprise BST-Gel-based injectable products that deliver biotherapeutics to their targeted site of action; Arthro-BST, an arthroscopic device used for the non-destructive evaluation of cartilage degradation and/or repair; and Mach-1, a micromechanical testing system for evaluating the mechanical properties of tissues and materials. In addition, it manufactures ultra pure chitosans under the Ultrasan name; and offers manufacturing and analytical services. The company was incorporated in 1994 and is based in Laval, Canada. On May 12, 2010, Biosyntech Inc. filed for administration under the Bankruptcy and Insolvency Act. Biosyntech Inc. is in reorganization.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News